What's in ECbiotech Taiwan's pipeline?

ECbiotech Taiwan has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ECbiotech Taiwan's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ecbiotech-taiwan.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

ECbiotech Taiwan — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ECbiotech Taiwan pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Extract of Agaricus blazei Murill	Extract of Agaricus blazei Murill	phase 3	Immunomodulator; natural product extract	Pattern recognition receptors (Dectin-1, TLR); macrophage and NK cell activation	Oncology; Immunology

Therapeutic area mix

Oncology; Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for ECbiotech Taiwan:

Cite this brief

Drug Landscape (2026). ECbiotech Taiwan — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ecbiotech-taiwan. Accessed 2026-05-17.